By down-regulating LKB1, Erianin reduces the expression of its downstream SIK2 and SIK3, thereby reducing the level of PARD3 and inhibiting the migration and invasion abilities of GC cells and its tumorigenesis in vivo. Here, PARD3 is linked to gastric cancer.